Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma.

For example, ~47.4% of the placebo group subsequently received antitumor treatments, and ~10.4% of them received PD-1/PD-L1 inhibitor treatments, which may have affected the final results (the P-value did not reach statistical significance).

also in 111,027 other papers

However, those patients in sorafenib group showed a notable trend towards OS prolongation.

also in 2,380 other papers